It was concluded that the BCL-2 genes are involved not only in the tumor initiation and tumor progression in patients with CRC, but also in the resistance to chemotherapy; furthermore, the abnormalities of BCL-2/Bcl-2 expression and activity were also related to neurodegenerative disorders, ischemia and autoimmune diseases [118,119,120,121]. This evidence concerns the gene BCL2 and autoimmune disease.